Advertisement

Drugs

, Volume 78, Issue 13, pp 1377–1382 | Cite as

Tecovirimat: First Global Approval

  • Sheridan M. Hoy
AdisInsight Report

Abstract

Tecovirimat (TPOXX®) is an orthopoxvirus-specific antiviral drug developed by SIGA Technologies in conjunction with the US Department of Health and Human Services’ Biomedical Advances Research and Development Authority. It acts by inhibiting the activity of the orthopoxvirus VP37 envelope wrapping protein, thereby preventing the formation of egress-competent enveloped virions, which are essential for dissemination of the virus in the host. In July 2018, oral tecovirimat was approved in the USA for the treatment of human smallpox disease caused by variola virus in adults and paediatric patients weighing ≥ 13 kg. Tecovirimat was approved under the US FDA’s Animal Rule, in which marketing approval is based on its efficacy in relevant animal models. An intravenous formulation of tecovirimat is undergoing phase I development for the treatment of smallpox infection. This article summarises the milestones in the development of tecovirimat leading to this first approval for the treatment of human smallpox disease in adults and paediatric patients weighing ≥ 13 kg.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sheridan Hoy is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    US FDA. FDA approves the first drug with an indication for treatment of smallpox; 2018. http://www.fda.gov/. Accessed 16 July 2018.
  2. 2.
    Grosenbach DW, Jordan R, Hruby DE. Development of the small-molecule antiviral ST-246R as a smallpox therapeutic. Future Virol. 2011;6(5):653–71.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Jordan R, Leeds JM, Tyavanagimatt S, et al. Development of ST-246R for treatment of poxvirus infections. Viruses. 2010;2(11):2409–35.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    SIGA Technologies Inc. TPOXX (tecovirimat) capsules for oral use: US prescribing information; 2018. http://www.fda.gov/. Accessed 26 July 2018.
  5. 5.
    Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(1):44–53.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    SIGA Technologies Inc. U.S. Food and Drug Administration approves SIGA Technologies’ TPOXX® (tecovirimat) for the treatment of smallpox [media release]. 13 July 2018. http://www.siga.com/.
  7. 7.
    Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol. 2005;79(20):13139–49.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Leeds JM, Fenneteau F, Gosselin NH, et al. Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. Antimicrob Agents Chemother. 2013;57(3):1136–43.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, et al. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother. 2012;56(9):4900–5.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Jordan R, Tien D, Bolken TC, et al. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother. 2008;52(5):1721–7.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, et al. Pharmacokinetic comparison of a single oral dose of polymorph form I versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers. Antimicrob Agents Chemother. 2012;56(7):3582–6.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Jordan R, Chinsangaram J, Bolken TC, et al. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother. 2010;54(6):2560–6.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations